Clinical analysis of hairy cell leukemia: the rare indolent hematological malignancy

CONCLUSION: HCL is a rare clinically indolent hematological tumor, which is sensitive to Cladribine, with the emergence of precision treatments such as the novel molecular-targeted drugs and immunotherapy also plays an indispensable role in clinical practice of HCL.PMID:38463575 | PMC:PMC10918128 | DOI:10.62347/WFQM3371

Source: American Journal of Translational Research - March 11, 2024 Category: Research Authors: He Huang Yanquan Liu Minjuan Zeng Xiaojun Chen Yue Yin Huidong Guo Zhimin Yan Jie Lin Source Type: research